Ardelyx, Inc.
Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators

Abstract:

The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L.sub.1, L.sub.2, A, B, R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are described herein. ##STR00001##